5β‐estrane‐3β,17β‐diol | 37795-40-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5β‐estrane‐3β,17β‐diol
• 英文别名: 5β-estranediol-(3β.17β)；(10S)-3c.17c-Dihydroxy-13c-methyl-(5cH.8cH.9tH.10rH.14tH)-hexadecahydro-1H-cyclopenta[a]phenanthren；5β-Oestrandiol-(3β.17β)；3β.17β-Dihydroxy-13-methyl-5β-gonan；19-nor-5β-androstan-3β,17β-diol；5β-estrane-3β,17β-diol；(3S,5R,8R,9R,10S,13S,14S,17S)-13-methyl-1,2,3,4,5,6,7,8,9,10,11,12,14,15,16,17-hexadecahydrocyclopenta[a]phenanthrene-3,17-diol
• CAS: 37795-40-7
• 化学式: C₁₈H₃₀O₂
• 分子量: 278.435
• InChiKey: QNKATSBSLLYTMH-LPBQTOPCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5β‐estrane‐3β,17β‐diol 、 乙酰溴-Alpha-D-葡萄糖酮酸甲基酯 在 silver carbonate 作用下， 以 甲苯 为溶剂， 反应 72.0h， 生成
  参考文献：
  名称：

  电离和碰撞诱导类固醇bisglucuronides的解离。

  摘要：

  对类固醇代谢的研究对于提高在运动药物测试中滥用的合成代谢雄激素类固醇（AASs）的检测能力至关重要。在人体中，葡萄糖醛酸偶联物是AAS中最丰富的II期代谢产物。双葡糖醛酸化是在同一分子上两个分离的官能团与葡糖醛酸共轭的反应。这些代谢物尚未深入研究类固醇，可能是兴奋剂控制的有趣标志。本工作的目的是研究类固醇双葡糖醛酸苷的离子化和碰撞诱导的解离，以便能够开发质谱分析策略，以便在使用AAS后在尿液样品中检测它们。由于类固醇bisglucuronides不可商购，定性合成了其中的19种化合物，以研究其质谱行为。Bisglucuronides在正离子模式下离子化为[M + NH4] +，在负离子模式下离子化为[MH]-和[M-2H] 2-。正离子模式下甾体双葡糖醛酸苷的最特异产物离子是由387和405 Da的中性损失引起的（对应于[M + NH4 -NH3 -2gluc-H2 O] +和[M + NH4

  DOI：

  10.1002/jms.3973
• 作为产物：
  描述：

  雌二醇 生成 5β‐estrane‐3β,17β‐diol
  参考文献：
  名称：

  TANG, G. Z.;PENG, C. T., J. LABELL. COMPOUNDS AND RADIOPHARM., 25,(1988) N 6, 585-601

  摘要：

  DOI：

文献信息

• Isomeric estrane derivatives
  作者：R.E. Counsell

  DOI：10.1016/0040-4020(61)80027-6

  日期：1961.1

  Various 3,17-oxygenated isomeric estrane derivatives have been synthesized as possible metabolites of 19-norsteroids. Methods employed to establish configurations are described and biological data on some of the more pertinent compounds is presented.

  已合成了各种3,17-氧化异构雌激素衍生物，作为19-降糖甾体的可能代谢产物。描述了用于建立构型的方法，并提供了一些更相关化合物的生物学数据。
• Pharmaceutical compositions and treatment methods-7
  申请人：Ahlem Nathaniel Clarence

  公开号：US20050282732A1

  公开（公告）日：2005-12-22

  The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

  本发明提供了由式 1 类固醇（如 16α-溴-3β-羟基-5α-雄甾烷-17-酮半水合物）和一种或多种赋形剂组成的组合物，其中组合物通常包含小于约 3% 的水。这些组合物可用于制造改良药物制剂。本发明还提供了类固醇化合物（如 16α-溴-3β-羟基-5α-雄甾烷-17-酮的类似物）的间歇给药方法和用于此类给药方案的组合物。本发明进一步提供了使用某些类固醇和类固醇类似物抑制病原体（病毒）复制、改善与免疫失调相关的症状和调节受试者免疫反应的组合物和方法。本发明还提供了制造和使用这些免疫调节组合物和制剂的方法。
• Phantoms for Cross-Calibration of Dual Energy X-ray Absorptiometry Measurements in Infants
  作者：Mouhanad Hammami、Jean-Charles Picaud、Christoph Fusch、Elaine M. Hockman、Jacques Rigo、Winston W.K. Koo

  DOI：10.1080/07315724.2002.10719230

  日期：2002.8

  Objective: To test the suitability of phantoms to cross-calibrate body composition measurements in small subjects among different dual energy X-ray absorptiometry (DXA) instruments.Methods: A set of four phantoms with total weights 1520g, 3140g, 4650g and 7490g were made with low cost and easily available materials. Each phantom was made from assembling polyethylene bottles (100 to 1000 mL) filled with either pure olive oil or electrolyte solution in different combinations, and borosilicate tubes (3 and 5 mL) and flexible polypropylene tubing filled with calcium carbonate. Triplicate measurements of each of the four phantoms were performed with three pencil beam densitometers made by the same manufacturer (Hologic Inc., Waltham, MA): two QDR 2000 (University of Liege, Liege, Belgium, and Wayne State University, Detroit, Michigan) and a QDR1500 (University Children's Hospital, Greifswald, Germany) using infant whole body-scanning mode and analyzed with software V5.73P.Results: DXA measured total weight, or bone, lean and fat masses, from one center were highly predictive of DXA measurements from the other centers with an adjusted r(2) of 0.94 to 1.00, p < 0.001. This was the case whether the measurements from single scan or from average of triplicate scans were used in the analysis.Conclusions: Systematic corrections, in the form of linear transformations, are possible to allow comparison of clinical data generated from different centers. Different size phantoms can be made to accommodate the varying range of weights and body composition of study subjects.